Strong Customer Gains and Standout US Growth Helps Entersekt Solidify Market Position
16.8.2023 12:00:00 EEST | Business Wire | Press release
Entersekt, a global leader in transaction authentication solutions for financial fraud prevention, today announced strong growth in both revenue and number of customers, fueled by continued US expansion and strategic partnerships. Since the investment by Accel-KKR in fiscal 2022, Entersekt has seen its business outside of South Africa accelerate rapidly with contracted annual recurring revenue increase by 191%, and nearly 220% growth in US-based customers in fiscal 2023 alone.
“Our solid growth in a difficult global business climate is testament to Entersekt’s innovation and expertise addressing emerging fraud threats,” said Schalk Nolte, Entersekt CEO. “Our reputation of delivering the highest level of security to financial institutions across all digital channels without compromising user experience is capturing the attention of decision makers – many of whom now recognize the urgent need to adopt more robust authentication methods to replace the traditional approaches that are proving to be vulnerable to increasingly sophisticated fraud attempts.”
“We are particularly pleased with our performance in the US which is nearing hypergrowth. The region remains a key focus for the year ahead and we have identified key partners and talent who are well known in the industry to help us to accelerate the current trajectory. The market has shown itself eager to adopt our technology which has a proven track record with financial institutions around the world,” Nolte explained.
“As fraud and financial crime continues to threaten financial institutions around the world, the opportunity for innovative technology firms to help mitigate these risks is greater than ever,” said Julie Conroy, Head of Risk Insights at Datos Insights. “Entersekt’s steady growth and expansion is a key indicator of the appetite for FIs of all sizes to seek solutions that can reduce fraud while ensuring an optimal user experience.”
Fiscal 2023 Performance Highlights
Market-leading fraud prevention Innovations
The Entersekt team continued to innovate well ahead of the industry curve, with three new patents granted in FY2023, adding to the more than 60 existing technology patents. These include Context Aware™ Authentication which is the first cross-channel fraud prevention to consider the originating channel, the transaction context, the analysis and orchestration of both active and silent risk signals, the available authentication mechanisms, as well as the customer’s choice to determine the most appropriate authentication journey - all in real-time.
“Many banks continue to struggle with siloed authentication mechanisms, with different solutions for online banking, in-branch offerings, call centers, digital payments and open banking, with each using its own authentication technology. We're providing the ability to break down all those silos and have one common authentication platform across all the various channels. Not only does this provide a much better user and customer experience, but also helps orchestrate all that data to help banks make better decisions,” Nolte said.
New strategic channel and technology partnerships
The Entersekt team continued to solidify new partnerships in all regions, improving it’s go-to-market scale and creating new market opportunities. By supporting pre-integration, these partnerships enabled banks to quickly and easily deploy Entersekt’s state-of-the-art authentication technology. Most recently, Entersekt’s biometric authentication technology was integrated into Q2’s Digital Banking Platform, adding biometric authentication capabilities to the Q2 online and mobile banking applications.
Expanded senior management
To support the significant growth and opportunity in the US market, Entersekt made ten new director, VP or C-level hires in the US in FY23. Its executive team and company headquarters is now based both in the US and South Africa, showcasing the importance of and commitment to regional representation.
Three new C-level appointments, all with decades of leadership experience, include Matt Loos as Chief Revenue Officer, Pradheep Sampath as Chief Product Officer and Frank Moreno as Chief Marketing Officer.
- Loos joins Entersekt with over 20 years of leadership experience at companies like Fifth Third Bank, Cardinal Commerce and Mastercard.
- Sampath has led new product initiatives for over 20 years, scaling SaaS, mobile and API-based products for companies like ID.me and GXS.
- Moreno’s experience includes senior marketing leadership roles spanning over 20 years with tech companies such as Bottomline and Datawatch.
More growth on the horizon
Looking ahead, Nolte said the industry must prepare for the continued challenges of account takeover fraud schemes and authorized push payment fraud, saying the rise of real-time payments, particularly through mobile apps, has introduced a need for faster and more effective fraud detection mechanisms.
“Our vision for the future is centered around becoming a leading force in the digital landscape, revolutionizing the way people conduct secure transactions on digital platforms. With the backing of our US-based investors, key partners and a customer-centric approach, we are poised for exceptional success in the year ahead and beyond,” Nolte said.
About Entersekt
Entersekt ensures that digital financial transactions are secure and free from unnecessary friction. The company provides a single cross-channel platform for financial services institutions to meet authentication requirements and optimize user experiences. With a range of options available for deployment and configuration, Entersekt’s solutions are fully customizable across all channels and devices. A strong track record of over ten years’ working with leading financial services institutions across the United States, Europe, and Africa, combined with multiple patented security innovations, has established Entersekt as a global industry leader in authentication. Backed by companies like Silicon Valley-based Accel-KKR, one of the world’s top private equity firms, Entersekt continues to expand its footprint across key regions. For more information, visit entersekt.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230816112272/en/
Contact information
Frank Moreno
Chief Marketing Officer
frank@entersekt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
